Author Login IJIRT Partner Network (IPN) Login

PLGA LOADED RIFAMPICIN FOR TREAT DIVERSE MYCOBACTERIAL INFECTIONS

  • Unique Paper ID: 165721
  • Volume: 11
  • Issue: 1
  • PageNo: 1454-1457
  • Abstract:
  • The aim of the present work was to minimize or prevent the degradation of rifampicin, the antitubercular drug in gastric pH condition to improve the stability and therapeutic efficacy of the drug. The study was carried out by preparing Rifampicin loaded PLGA nanoparticles using ascorbic acid as an antioxidant. Dug loaded nanoparticles were fabricated by a multistep emulsion procedure and evaluations of the prepared nanoparticles were then carried out by various methods. In this study four types of formulations were prepared. Formulation 1 (F1) is rifampicin alone loaded PLGA nanoparticles, formulation II (F2) is rifampicin – ascorbic acid (1:1) loaded PLGA nanoparticles, formulation III (F3) is rifampicin - ascorbic acid (1:2) loaded PLGA nanoparticles and formulation IV (F4) is rifampicin – ascorbic acid (1:3) loaded PLGA nanoparticles. The study concluded that ascorbic acid can minimize the degradation of rifampicin in acidic pH condition and thus improves the stability and bioavailability of rifampicin. The results also demonstrate that there is a statistically significant change in the percentage drug degradation profile when the concentration of ascorbic acid was increased.
Download article email to a friend

Cite This Article

  • ISSN: 2349-6002
  • Volume: 11
  • Issue: 1
  • PageNo: 1454-1457

PLGA LOADED RIFAMPICIN FOR TREAT DIVERSE MYCOBACTERIAL INFECTIONS

Related Articles

Impact Factor
8.01 (Year 2024)
UGC Approved
Journal no 47859

Join Our IPN

IJIRT Partner Network

Submit your research paper and those of your network (friends, colleagues, or peers) through your IPN account, and receive 800 INR for each paper that gets published.

Join Now

Latest Publication

Archive

View More

Recent Conferences

NCSEM 2024

National Conference on Sustainable Engineering and Management - 2024 Last Date: 15th March 2024

Submit inquiry